150 related articles for article (PubMed ID: 20668965)
21. Molecular stratification of triple-negative breast cancers.
Perou CM
Oncologist; 2011; 16 Suppl 1():61-70. PubMed ID: 21278442
[TBL] [Abstract][Full Text] [Related]
22. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas.
Lal P; Tan LK; Chen B
Am J Clin Pathol; 2005 Apr; 123(4):541-6. PubMed ID: 15743737
[TBL] [Abstract][Full Text] [Related]
23. Urinary bladder metastasis from breast cancer with heterogeneic expression of estrogen and progesterone receptors.
Lin WC; Chen JH
J Clin Oncol; 2007 Sep; 25(27):4308-10. PubMed ID: 17878482
[No Abstract] [Full Text] [Related]
24. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
25. Triple-negative breast cancer: therapeutic options.
Cleator S; Heller W; Coombes RC
Lancet Oncol; 2007 Mar; 8(3):235-44. PubMed ID: 17329194
[TBL] [Abstract][Full Text] [Related]
26. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?
Park YH; Kim ST; Cho EY; Choi YL; Ok ON; Baek HJ; Lee JE; Nam SJ; Yang JH; Park W; Choi DH; Huh SJ; Ahn JS; Im YH
Breast Cancer Res Treat; 2010 Feb; 119(3):653-61. PubMed ID: 19957028
[TBL] [Abstract][Full Text] [Related]
27. [Prevalence of hormonal receptors and human epidermal growth factor receptor 2 in Mexican female patients with breast cancer].
Pérez G; Aranda C; Olivares IM; García JR
Med Clin (Barc); 2014 Sep; 143(5):231-2. PubMed ID: 24183125
[No Abstract] [Full Text] [Related]
28. Identification of oestrogen, progesterone receptor and human epidermal growth factor receptor 2 expression in mediastinal metastases of breast cancer obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
Serra P; Sanz-Santos J; Castellà E; Cirauqui B; Andreo F; Llatjós M; Avila M; Margelí M; Serrano L; Centeno C; Quiroga V; Torky M; Ruiz-Manzano J
Cytopathology; 2018 Feb; 29(1):35-40. PubMed ID: 29119620
[TBL] [Abstract][Full Text] [Related]
29. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant chemotherapy is not for everyone.
Henderson IC
Breast Cancer Res Treat; 2010 Aug; 123(1):159-62. PubMed ID: 20549338
[No Abstract] [Full Text] [Related]
31. Cancer cell-associated MT1-MMP promotes blood vessel invasion and distant metastasis in triple-negative mammary tumors.
Perentes JY; Kirkpatrick ND; Nagano S; Smith EY; Shaver CM; Sgroi D; Garkavtsev I; Munn LL; Jain RK; Boucher Y
Cancer Res; 2011 Jul; 71(13):4527-38. PubMed ID: 21571860
[TBL] [Abstract][Full Text] [Related]
32. Pattern of metastatic spread in triple-negative breast cancer.
Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
Breast Cancer Res Treat; 2009 May; 115(2):423-8. PubMed ID: 18543098
[TBL] [Abstract][Full Text] [Related]
33. Inducing or Preventing Subsequent Malignancies for Breast Cancer Survivors? Double-edged Sword of Estrogen Receptor and Progesterone Receptor.
Hu ZY; Xiao H; Xiao M; Tang Y; Sun J; Xie ZM; Ouyang Q
Clin Breast Cancer; 2018 Oct; 18(5):e1149-e1163. PubMed ID: 29885789
[TBL] [Abstract][Full Text] [Related]
34. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer.
Ranger GS; Thomas V; Jewell A; Mokbel K
Anticancer Res; 2004; 24(4):2349-51. PubMed ID: 15330183
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
[TBL] [Abstract][Full Text] [Related]
36. Src: a potential target for the treatment of triple-negative breast cancer.
Tryfonopoulos D; Walsh S; Collins DM; Flanagan L; Quinn C; Corkery B; McDermott EW; Evoy D; Pierce A; O'Donovan N; Crown J; Duffy MJ
Ann Oncol; 2011 Oct; 22(10):2234-40. PubMed ID: 21357651
[TBL] [Abstract][Full Text] [Related]
37. ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.
Keshgegian AA
Breast Cancer Res Treat; 1995 Aug; 35(2):201-10. PubMed ID: 7647342
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
Perez EA; Patel T; Moreno-Aspitia A
Breast Cancer Res Treat; 2010 Jun; 121(2):261-71. PubMed ID: 20229176
[TBL] [Abstract][Full Text] [Related]
39. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia.
Arafah M
Turk Patoloji Derg; 2012; 28(1):38-43. PubMed ID: 22207430
[TBL] [Abstract][Full Text] [Related]
40. Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer.
Warm M; Kates R; Grosse-Onnebrink E; Stoff-Khalili M; Hoopmann M; Mallmann P; Thomas A; Harbeck N
Anticancer Res; 2010 Oct; 30(10):4251-9. PubMed ID: 21036749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
